Waters Company expands into biosciences and diagnostics

Waters Company, a worldwide supplier of analytical devices and software program serving biotechnology, pharmaceutical, and medical laboratories, is repositioning its development profile by way of the acquisition of Becton Dickinson’s (BD) Biosciences and Diagnostic Options enterprise.

The deal meaningfully expands Waters’ publicity to biologics, diagnostics, and controlled laboratory workflows whereas including a considerable base of recurring income.

On the JP Morgan Healthcare Convention on 12 January, Waters detailed the strategic rationale, synergy alternatives, and anticipated long-term monetary influence, arguing the mixture can drive above-market development and margin enlargement over the approaching years.

BD’s biosciences and diagnostic options unit is a ~$3.3bn enterprise that generated roughly 5% annual development from 2019 to 2024. The income profile is notably sturdy: about 80% is recurring, supported by a big put in base and ongoing demand for consumables, reagents, and repair. The enterprise can be geographically diversified, with roughly 50% of income from the Americas, ~30% from Europe, and ~20% from Asia-Pacific/China.

For Waters, the acquisition accelerates a shift towards faster-growing, extra defensible finish markets whereas complementing its core strengths in analytical science. It additionally strengthens Waters’ diagnostics technique. Waters’ LC-MS diagnostics enterprise (~$265m in annual income) has been rising within the high-single digits to low-double digits however has confronted limits in business scale. BD’s world business, service, regulatory, and automation infrastructure is anticipated to increase Waters’ attain and speed up development in areas reminiscent of therapeutic drug monitoring, endocrinology, and different medical functions.

Waters expects roughly $200m of price synergies inside three years of closing, with potential to exceed $300m primarily based on comparable historic integrations. Recognized synergies embody manufacturing and provide chain efficiencies, business and repair optimisation, and financial savings throughout R&D and SG&A, with significant advantages starting as early as 2026.

Income synergies are anticipated from three primary levers: business execution, enlargement into higher-growth adjacencies, and cross-selling. Excessive-growth adjacencies are anticipated to generate about $150m of incremental income by 12 months 5, pushed by alternatives reminiscent of movement cytometry in regulated labs, enhanced bioseparations choices, and quicker LC-MS diagnostics adoption. Cross-selling is especially related given BD’s power in educational, authorities, biotech, and drug discovery accounts the place Waters has traditionally had much less penetration.

Total, the transaction shifts Waters from a primarily mid-single-digit development combine towards a portfolio extra weighted to low double-digit and double-digit development areas. Financially, Waters is focusing on roughly 7% income CAGR over the following 5 years, roughly 500 foundation factors of margin enlargement, and powerful EPS development.

Enroll right here to obtain each day updates on the most recent healthcare trade developments rising from the JP Morgan Healthcare convention 2026.

“Waters Company expands into biosciences and diagnostics” was initially created and revealed by Medical Gadget Community, a GlobalData owned model.

The knowledge on this website has been included in good religion for normal informational functions solely. It isn’t supposed to quantity to recommendation on which it’s best to rely, and we give no illustration, guarantee or assure, whether or not specific or implied as to its accuracy or completeness. You should get hold of skilled or specialist recommendation earlier than taking, or refraining from, any motion on the idea of the content material on our website.